Cue Biopharma's top three insider shareholders as of May 30, 2026 are Cameron Gray (Director, 687.05K shares), Pasha Sarraf (Director, 323.86K shares), Daniel R Passeri (Chief Executive Officer, 164.58K shares).
| Holder | Position | Shares (Direct) | Shares (Indirect) | Report Date |
|---|---|---|---|---|
| Daniel R Passeri | Chief Executive Officer | 164,578 | 0 | 18 Dec, 2024 |
| Peter A Kiener | - | 357 | 0 | 27 Mar, 2023 |
| Cameron Gray | - | 687,049 | 0 | 16 Jun, 2022 |
| Kerri-Ann Millar | Chief Financial Officer | 14,311 | 0 | 23 Aug, 2022 |
| Anish Suri | President And Cso | 135,638 | 0 | 29 Aug, 2023 |
| Pasha Sarraf | - | 323,857 | 0 | 02 Jan, 2026 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 09 Apr, 2026 | Daniel G. Baker | Stock Option (right to buy) | A | 100,000 | $0.00 | 100,000 | D | A |
| 09 Apr, 2026 | Lucinda Warren | Stock Option (right to buy) | A | 250,000 | $0.00 | 250,000 | D | A |
| 09 Apr, 2026 | Colin Sandercock | Stock Option (right to buy) | A | 200,000 | $0.00 | 200,000 | D | A |
| 09 Apr, 2026 | Colin Sandercock | Stock Option (right to buy) | A | 200,000 | $0.00 | 200,000 | D | A |
| 02 Jan, 2026 | Pamela Garzone | Stock Option (right to buy) | A | 24,400 | $0.00 | 24,400 | D | A |
| 02 Jan, 2026 | Pasha Sarraf | Stock Option (right to buy) | A | 24,400 | $0.00 | 24,400 | D | A |
| 02 Jan, 2026 | Patrick Verheyen | Stock Option (right to buy) | A | 24,400 | $0.00 | 24,400 | D | A |
| 02 Jan, 2026 | Patrick Verheyen | Stock Option (right to buy) | A | 24,400 | $0.00 | 24,400 | D | A |
| 02 Jan, 2026 | Pasha Sarraf | Stock Option (right to buy) | A | 24,400 | $0.00 | 24,400 | D | A |
| 02 Jan, 2026 | Patrick Verheyen | Stock Option (right to buy) | A | 24,400 | $0.00 | 24,400 | D | A |
| 02 Jan, 2026 | Pasha Sarraf | Stock Option (right to buy) | A | 24,400 | $0.00 | 24,400 | D | A |
| 02 Jan, 2026 | Peter A Kiener | Stock Option (right to buy) | A | 24,400 | $0.00 | 24,400 | D | A |
| 02 Jan, 2026 | Jill Marie Broadfoot | Stock Option (right to buy) | A | 24,400 | $0.00 | 24,400 | D | A |
| 02 Jan, 2026 | Pamela Garzone | Stock Option (right to buy) | A | 24,400 | $0.00 | 24,400 | D | A |
| 02 Jan, 2026 | Pamela Garzone | Stock Option (right to buy) | A | 24,400 | $0.00 | 24,400 | D | A |
| 30 Dec, 2025 | Pasha Sarraf | Common Stock | A | 4,229 | $0.31 | 4,229 | D | P |
| 30 Dec, 2025 | Pasha Sarraf | Common Stock | A | 4,229 | $0.31 | 4,229 | D | P |
| 30 Dec, 2025 | Pasha Sarraf | Common Stock | A | 4,229 | $0.31 | 4,229 | D | P |
| 30 Dec, 2025 | Pasha Sarraf | Common Stock | A | 77,148 | $0.30 | 81,377 | D | P |
| 30 Dec, 2025 | Pasha Sarraf | Common Stock | A | 77,148 | $0.30 | 81,377 | D | P |